Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 12, 2015
Previous Article Next Article

Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

Author affiliations

Abstract

Neurodegenerative disease appears as a result of genomic lesions which lead to alterations at multiple levels like genomic product and biological pathways. It involves destruction of existing neuroprotective mechanisms inside body which initiates the cellular changes involved in processing of these insidious disorders. Phosphodiesterases that are crucial for degradation of cAMP and cGMP have been puissant in memory retrieval. Overwhelming therapeutic credential of PDE5 inhibitors have triggered interests in PDE inhibitors. Almost every PDE member has marked its presence in the CNS devising them as enticing sources of novel protein targets for curing ND. This review describes a selection of recent findings and advancements with regards to PDE genes that are crucial for exploring pharmacological routes to ND.

Graphical abstract: Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

Back to tab navigation

Article information


Submitted
18 Sep 2015
Accepted
05 Nov 2015
First published
12 Nov 2015

Med. Chem. Commun., 2015,6, 2063-2080
Article type
Review Article

Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

T. Umar and N. Hoda, Med. Chem. Commun., 2015, 6, 2063
DOI: 10.1039/C5MD00419E

Search articles by author

Spotlight

Advertisements